Viemed Healthcare, a U.S. provider of home medical equipment and post-acute healthcare services, announced it will present at the 20th Annual LD Micro Main Event on October 20, 2026, in Los Angeles. CEO Casey Hoyt and management will represent the company, highlighting Viemed's focus on respiratory, chronic care, and women's health services delivered at home. This event offers Viemed an opportunity to connect with investors and showcase its technology-enabled care model. The presentation will be webcast for broader access.
Viemed Healthcare, Inc. is set to present at the 20th Annual LD Micro Main Event. For readers following the health sector, here is Pluang's market snapshot as of Oct 06, 2026 17:51 WIB: Out of 100 priced US health-sector stocks tradable on Pluang, 67 rose and 25 fell today. Notable movers include BNGO at USD 1.50 with a 3.81% increase and a typical hold time on Pluang of 49 days, NUWE at USD 0.72 up 3.72% with 76% buy order activity, and FLNA at USD 0.90 rising 3.45% with 92% buy order activity.
Senseonics Holdings has begun the first human clinical trial of Freedom, a next-generation continuous glucose monitoring (CGM) system designed without an external on-body transmitter. This implantable device communicates directly with mobile devices ...
Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...
FOREWARN, a safety solutions provider for real estate professionals, introduced Community Alerts, a new feature that allows agents to flag phone numbers after concerning interactions. This alert is instantly shared across its network of over 443,000 ...
Franklin Electric Co., Inc. announced a quarterly cash dividend of $0.28 per share, payable on November 19, 2026, to shareholders of record as of November 5, 2026. This dividend reflects the company's ongoing commitment to returning value to its shar...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
